Physiological and pathological properties of α-synuclein

Cellular and Molecular Life Sciences

Volumn 64, Issue 17, 2007, Pages 2194-2201

  Tofaris, G K ^a   Spillantini, M G ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Synuclein; synucleinopathies; Lewy body; Neurodegeneration; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN;

DNA MODIFICATION; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW;

ALPHA-SYNUCLEIN; HUMANS; LEWY BODIES; PARKINSON DISEASE; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY;

EID: 34548318990     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-007-7217-5     Document Type: Review

References (82)

1. Forno, L. S. (1996) Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259-272.
2. Tofaris, G. K. and Spillantini, M. G. (2005) α-Synuclein dysfunction in Lewy body diseases. Mov. Disorders 20, S37-S44.
3. Arai, K., Kato, N., Kashiwado, K. and Hattori, T. (2000) Pure autonomic failure in association with human α-synucleinopathy. Neurosci. Lett. 296, 171-173.
4. Arawaka, S., Saito, Y., Murayama, S. and Mori, H. (1998) Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein. Neurology 51, 887-889.
5. Wakabayashi, K., Yoshimoto, M., Fukushima, T., Koide, R., Horikawa, Y. and Takahashi, H. (1999) Widespread occurrence of α-synuclein/NACP- immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies. Neuropathol. Appl. Neurobiol. 25, 363-368.
6. Yamazaki, M., Arai, Y., Baba, M., Iwatsubo, T., Mori, O., Katayama, Y. and Oyanagi, K. (2000) α-Synuclein inclusions in amygdala in the brains of patients with the Parkinsonism-Dementia complex of Guam. J. Neuropathol. Exp. Neurol. 59, 585-591.
7. Lippa, C. F., Schmidt, M. L., Lee, V. M.-Y. and Trojanowski, J. Q. (1999) Antibodies to α-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimers disease. Ann. Neurol. 45, 353-357.
8. Spillantini, M. G., Crowther, R. A., Jakes, R., Cairns, N. J., Lantos, P. L. and Goedert, M. (1998) Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205-208.
9. Tofaris, G. K, Revesz, T., Jacques, T., Papacostas, S. and Chataway, J. (2007) Adult-onset neurodegeneration with brain iron accumulation and cortical α-synuclein and tau pathology: a distinct clinico-pathological entity. Arch. Neurol. 64, 280-282.
10. Kotzbauer, P. T., Trojanowski, J. Q. and Lee, V. M.-Y. (2001) Lewy body pathology in Alzheimer's disease. J. Mol. Neurosci. 17, 225-232.
11. Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A. and Lansbury, P. T (1996) NACP, a protein implicated in Alzheimer's disease and learning is natively unfolded. Biochemistry 35, 13709-13715.
12. Davidson, W. S., Jonas, A., Clayton, D. F. and George, J. M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449.
13. Jenco, J. M., Rawlingson, A., Daniels, B. and Morris, A. J. (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α- and β-synucleins. Biochemistry 37, 4901-4909.
14. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E. Shinsky, N., Verdugo, J. M., Armanini, M., Ryan, A et al. (2000) Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252.
15. Murphy, D. D., Rueter, S. M., Trojanowski, J. Q. and Lee, V. M.-Y. (2000) Synucleins are developmentally expressed and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214-3220.
16. George, J. M., Jin, H., Woods, W. S. and Clayton, D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361-372.
17. Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O. M. and Sudhof, T. C. (2005) alpha-Synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123, 383-396.
18. Dev, K. K., Hofele, K., Barbieri, S., Buchman, V. L. and van der Putten, H. (2003) Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacolology 45, 14-44.
19. Engelender, S., Kaminsky, Z., Guo, X., Sharp, A. H., Amaravi, R. K., Kleiderlein, J. J., Margolis, R. L., Troncoso, J. C., Lanahan, A. A., Worley, P. F. et al. (1999) Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22, 110-114.
20. Ostrerova-Golts, N., Petrucelli, L., Farer, M., Mehta, N., Alexander, P., Choi, P., Palacino J, Hardy, J., Lee, J. M. and Wolozin, B. (1999) α-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19, 5782-5791.
21. Iwata, A., Maruyama, M., Kanazawa, I. and Nukina, N. (2001) α-Synuclein affects the MAP kinase pathway and accelerates cell death. J. Biol. Chem. 276, 45320-45329.
22. Alves da Costa, C., Ancolio, K. and Checler, F. (2000) Wild-type but not Parkinson's disease-related Ala-53-Thr mutant α-synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem. 275, 24065-24069.
23. Lee, M., Hyun, D., Halliwell, B. and Jenner, P. (2001) Effect of the over-expression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J. Neurochem. 76, 998-1009
24. Hashimoto, M., Hsu, L. J., Rockenstein, E., Takenouchi, T., Mallory, M. and Masliah, E. (2002) α-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress signalling pathway in neuronal cells. J. Biol. Chem. 277, 11465-11472.
25. Michell, A. W., Tofaris, G. K., Gossage, H., Tyers, P., Spillantini, M. G. and Barker, R. A. (2007) The effect of truncated human α-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. Cell Transplant., in press.
26. Schneider, B. L., Seehus, C. R., Capowski, E. E., Aebischer, P., Zhang, S. C. and Svendsen, C. N. (2007) Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation. Hum. Mol. Genet. Epub ahead of print.
27. Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L., Kahle, P. J. and Haass, C. (2000) Constitutive phosphorylation of the Parkinson's disease associated α-synuclein. J. Biol. Chem. 275, 390-397.
28. Pronin, A. N., Morris, A. J., Surguchov, A. and Benovic, J. L. (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275, 26515-26522.
29. Negro, A., Brunati, A. M., Donella-Deana, A. Massimino, M. L. and Pinna, L. A. (2002) Multiple phosphorylation of α-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J. 16, 210-212.
30. Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R. and Goedert, M. (1997) α-synuclein in Lewy Bodies. Nature 338, 839-840.
31. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. and Goedert, M. (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469-6473.
32. Polymeropoulos, M. H., Lavendan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997) Mutation in α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
33. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schos, L. and Riess, O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
34. Zarranz, J. J., Alegre, J., Gomez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, Atares, B. et al. (2004) The new mutation E46K of alpha-synucleincauses Parkinson and Lewy body Dementia. Ann. Neurol. 55, 164-173.
35. Narhi, L., Wood, S. J., Steavenson, S., Jiang, Y., Wu, G. M., Anafi, D., Kaufman, S. A., Martin, F., Sitney, K., Denis, P. et al. (1999) Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 274, 9843-9846.
36. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M. and Crowther, R. A. (2000) Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross beta conformation. Proc. Natl. Acad. Sci. USA 97, 4897-4902.
37. Conway, K. A., Lee S.-L., Rochet, J. C., Ding, T. T., Williamson, R. E. and Lansbury, P. T. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97, 571-576.
38. Choi, W., Zibanee, S., Jakes, R., Serpell, L. C., Davletov, B., Crowther, R. A. and Goedert, M. (2004) Mutation E46K increases phospholipids binding and assembly into filaments of human alpha-synuclein. FEBS Lett. 576, 363-368.
39. Greenbaum, E. A., Graves, C. L., Mishizen-Eberz, A. J., Lupoli, M. A., Lynch, D. R., Englander, S. W., Axelsen, P. H. and Giasson, B. I. (2005) The E46K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem. 280, 7800-7807.
40. Chartier-Harlin, M. C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M. et al. (2004) alpha-Synuclein locus duplication as cause of familial Parkinson's disease. Lancet 364, 1167-1169.
41. Ibanez, P., Bonnet, A. M., Debarges, B., Lohmann, E., Tison, F., Pollak, P., Agid, Y., Durr, A., Brice, A. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169-1171
42. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R. et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
43. Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q. and Lee, V. M.-Y. (2002) Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human a-synuclein. Neuron 34, 521-533.
44. Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A. and Price, D. L. (2002) Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala53Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 99, 8968-8973.
45. Neumann, M., Kahle, P. J., Giasson, B. I., Ozmen, L., Borroni, E., Spooren, W., Muller, V., Odoy, S., Fujiwara, H., Hasegawa, M. et al. C. (2002) Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α- synucleinopathies. J. Clin. Invest. 110, 1429-1439.
46. Matsuoka, Y., Vila, M., Lincoln, S., McCormack, A., Dickson, D., Langston, W. J., McGowan, E., Farrer, M., Hardy, J., Duff, K. et al. (2001) Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8, 535-539.
47. Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J. and Bjorklund, A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2791.
48. Klein, R. L., King, M. A., Hamby, M. E. and Meyer, E. M. (2002) Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. (2002) Hum. Gene Ther. 13, 605-612.
49. Lo Bianco, C., Ridet, J.-L., Schneider, B. L., Deglon, N. and Aebischer, P. (2002) α-Synucleinopathy and selective dopaminergic neurone loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 99, 10813-10818.
50. Feany, M. B. and Bender, W. W. (2000)A Drosophila model of Parkinson's disease. Nature 404, 394-398.
51. Conway, K. A., Harper, J. D. and Lansbury, P. T. (1998) Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson's disease. Nat. Med. 4, 1318-1320.
52. Ostrerova-Golts, N., Petrucelli, L., Hardy, J., Lee, J. M., Farer, M. and Wolozin, B. (2000) The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20, 6048-6054.
53. Betarbet, R., Sherer, T. B., McKenzie, G., Garcia-Osuna, M., Panov, A. V. and Greenamyre, J. T. (2001) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306.
54. Giasson, B. I., Duda, J. E., Murray, I. V. J., Chen, Q., Souza, J. M., Hurting, H. I., Ischiropoulos, H., Trojanowski, J. Q. and Lee, V. M.-Y. (2000) Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290, 985-989.
55. Hodara, R., Norris, E. H., Giasson, B. I., Mishizen-Eberz, A. J., Lynch, D. R., Lee, V. M. and Ischiropoulos, H. (2004) Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J. Biol. Chem. 279, 47746-47753.
56. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K. and Iwatsubo, T. (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell. Biol. 4, 160-164.
57. Crowther, R. A., Jakes, R., Spillantini, M. G. and Goedert, M. (1998) Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett. 436, 309-312.
58. Murray, I. V., Giasson, B. I., Quinn, S. M., Koppaka, V., Axelsen, P. H., Ischiropoulos, H., Trojanowski, J. Q. and Lee, V.-M. Y. (2003) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42, 8530-8540.
59. Tofaris, G. K., Razzaq, A., Ghetti, B., Lilley, K. S. and Spillantini, M. G. (2003) Ubiquitination of α-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278, 44405-44411.
60. Tofaris, G. K., Reitbock, P. G., Humpy, T., Limounsine, S., O'Connell, M., Ghetti, B., Wilkinson, L., Goedert, M. and Spillantini, M. G. (2006) Pathological changes in dopaminergic neurons in mice transgenic for human α-synuclein (1-120): implications for Lewy body disorders. J. Neurosci. 26, 3942-3950.
61. Hashimoto, M., Takeda, A., Hsu, L. J., Takenouchi, T. and Masliah, E. (1999) Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J. Biol. Chem. 274, 28849-2885.
62. Antony, T., Hoyer, W., Cherny, D., Heim, G., Jovin, T. M. and Subramaniam, V. (2003) Cellular polyamines promote the aggregation of alpha-synuclein., J. Biol. Chem. 278, 3235-3240.
63. Fernandez, C. O., Hoyer, W., Zweckstetter, M., Jares-Erijman, E. A., Subramaniam, V., Griesinger, C. and Jovin, T. M. (2004) NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO, J. 23, 2039-2046.
64. Goers, J., Uversky, V. N. and Fink, A. L. (2003) Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro. Protein Sci. 12, 702-707.
65. Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos H and Lee, V. M. (2005) Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280, 21212-2129.
66. Bence, N. F., Sampat, R. M. and Kopito, R. R. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555.
67. Venkatraman, P., Wetzel, R., Tanaka, M., Nukina, N. and Goldberg, A. L. (2004) Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol. Cell 14, 95-104.
68. Lindersson, E., Beedholm, R., Hojrup, P., Moos, T., Gai, W., Hendil, K. B. and Jensen, P. H. (2004) Proteasomal inhibition by alpha-synuclein filaments and oligomers. J. Biol. Chem. 279, 12924-12934.
69. Tofaris, G. K., Layfield, R. and Spillantini, M. G. (2001) α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509, 22-26.
70. Liu, C.-W., Corboy, M. J., DeMartino, G. N. and Thomas, P. J. (2003) Endoproteolytic activity of the proteasome. Science 299, 408-411.
71. Auluck, P. K., Chan, H. Y. E., Trojanowski, J. Q., Lee, V. M. and Bonini, N. M. (2002) Chaperone suppression of α-synuclein toxicity in a Drosophila Model for Parkinson's disease. Science 295, 865-868.
72. Shin, Y., Klucken, J., Patterson, C., Hyman, B. T. and McLean, P. J. (2005) The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways., J. Biol. Chem. 280, 23727-23734.
73. Perrin, R. J., Woods, W. S., Clayton, D. F. and George, J. M. (2001) Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J. Biol. Chem. 276, 41958-41962.
74. Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A. and Selkoe, D. J. (2003) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583-595.
75. Volles, M. J., Lee, S. J., Rochet, J. C., Shtilerman, M. D., Ding, T. T., Kessler, J. C. and Lansbury, P. T. (2001) Vesicle permeabilization for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819.
76. Zhu, M., Li, J. and Fink, A. L. (2003) The association of alpha-synuclein with membranes affects bilayer structure, stability and fibril formation. J. Biol. Chem. 278, 40186-40197.
77. Mosharov, E. V., Staal, R. G., Bove, J., Prou, D., Hananiya, A., Markov, D., Poulsen, N., Larsen, K. E., Moore, C. M., Troyer, M. D. et al. (2006) Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci. 26, 9304-9311.
78. Conway, K. A., Rochet, J. C., Bieganski, R. M. and Lansbury, P. T. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346-1349.
79. Mazzulli, J. R., Mishizen, A. J., Giasson, B. I., Lynch, D. R., Thomas, S. A., Nakashima, A., Nagatsu, T., Ota, A. and Ischiropoulos, H. (2006) Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci. 26, 10068-10078.
80. Xu, J., Kao, S.-Y., Lee, F. J. S., Song, W., Jin, L.-W. and Yanker, B. A. (2002) Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease. Nat. Med. 8, 600-606.
81. Zhou, W., Schaak, J., Zawada, W. M. and Freed, C. R. (2002) Overexpression of human α-synuclein causes dopamine neurone death in primary human mesencephalic culture. Brain Res. 926, 42-50.
82. Trostchansky, A., Lind, S., Hodara, R., Oe, T., Blair, I. A., Ischiropoulos, H., Rubbo, H. and Souza, J. M. (2006) Interaction with phospholipids modulates alpha-synuclein nitration and lipi-protein adduct formation. Biochem. J. 393, 343-349.